Hepatocellular carcinoma: Can it be considered a controversial indication for liver transplantation in centers with high rates of hepatitis C?

Liver Transplantation

Volumn 8, Issue 11, 2002, Pages 1020-1027

  Moya, Angel ^a   Berenguer, Marina ^a   Aguilera, Victoria ^a   Juan, Fernando San ^a   Nicolás, David ^a   Pastor, Miguel ^a   López Andujar, Rafael ^a   Rayón, Miguel ^a   Orbis, Francisco ^a   Mora, Julio ^a   De Juan, Manuel ^a   Carrasco, Domingo ^a   Vila, Juan José ^a   Prieto, Martín ^a   Berenguer, Joaquín ^a   Mir, José ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; AZATHIOPRINE; CYCLOSPORIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS;

ADOLESCENT; ADULT; AGED; ARTICLE; ARTIFICIAL EMBOLISM; CANCER INVASION; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CAUSE OF DEATH; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; ORGAN DONOR; PREDICTION; PRIORITY JOURNAL; PROBABILITY; TREATMENT INDICATION; TREATMENT OUTCOME; TUMOR VOLUME;

EID: 0036849699     PISSN: 15276465     EISSN: None     Source Type: Journal    
DOI: 10.1053/jlts.2002.35664     Document Type: Article

References (14)

1. El-Serag HB, Mason AC, Key C. Trends in survival of patients with hepatocellular carcinoma. Between 1977 and 1996 in the United States. Hepatology 2001;33:62-65.
2. Okuda K, Ohtsuki T, Obata H, Tomimatsu M, Okazaki N, HasegawaH, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 1985;56:918-928.
3. Calvet X, Bruix J, Brú C, Ginés P, Vilana R, Solé M, et al. Natural history of hepatocellular carcinoma in Spain. Five year's experience in 249 cases. J Hepatol 1990;10:311-317.
4. Llovet JM, Bustamante J, Castells A, Vilana R, Ayuso MC, Sala M, et al. Natural history of untreated nonsurgical hepatocellular carcinoma: Rationale for the design and evaluation of therapeutic trials. Hepatology 1999;29:62-67.
5. Iwatsuki S, Gordon RD, Shaw BW, Starzl TE. Role of liver transplantation in cancer therapy. Ann Surg 1985;202:401-407.
6. Pichlmayr R, Weimann A, Ringe B. Indications for liver transplantation in hepatobiliary malignancy. Hepatology 1994;20: 33S-40S.
7. Iwatsuki S, Starzl TE, Sheahan DG, Yokoyama I, Demetris AJ, Todo S, et al. Hepatic resection versus transplantation for hepatocellular carcinoma. Ann Surg 1991;214:221-229.
8. Bismuth H, Chiche L, Adam R, Castaing D, Diamond T, Dennison A. Liver resection versus transplantation for hepatocellular carcinoma in cirrhotic patients. Ann Surg 1993;218:145-151.
9. Figueras J, Jaurrieta E, Valls C, Benasco C, Rafecas A, Xiol X, et al. Survival after liver transplantation in cirrhotic patients with and without hepatocellular carcinoma: A comparative study. Hepatology 1997;25:1485-1489.
10. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334:693-699.
11. Berenguer M, Ferrell L, Watson J, Prieto M, Kim M, Rayón M, et al. HCV-related fibrosis progression following liver transplantation: Increase in recent years. J Hepatol 2000;32:673-684.
12. Llovet JM, Fuster J, Bruix J. Intention-to-trear analysis of surgical treatment for early hepatocellular carcinoma: Resection versus transplantation. Hepatology 1999;30:1434-1440.
13. Berenguer M, Prieto M, San Juan F, Rayon JM, Martinez F, Carrasco D, et al. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology 2002;36:202-210.
14. Suarez Y, Franca ACV, Llovet JM, Fuster J, Bruix J. The current status of liver transplantation for primary hepatic malignancy. Clin Liver Dis 2000;4:591-605.